Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimes

Nephrology Dialysis Transplantation

Volumn 12, Issue 9, 1997, Pages 1890-1899

  Sawicki, P T ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antihypertensive treatment; Diabetic nephropathy; Glycaemic control; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; FELODIPINE; HEMOGLOBIN A1C; INSULIN; INULIN; METOPROLOL; RAMIPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INULIN CLEARANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; FELODIPINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INULIN; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL; TIME FACTORS;

EID: 0030845688     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.9.1890     Document Type: Article

References (44)

1. Borch-Johnson K, Andersen PK, Decken T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-596
2. Mogensen EC. Progression of nephropathy in long term diabetics with proteinuria and effect of antihypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-388
3. Parving HH, Smidt UM, Andersen AR, Svendsen A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179
4. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 1983; 74: 256-264
5. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 292-300
6. Mogensen CE. Diabetic renal disease. The quest for normotension - and beyond. Diabetic Med 1995; 12: 756-769
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
8. Maki D, Ma JZ, Luis T, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080
9. Pickering T. Blood pressure measurement and detection of hypertension. Lancet 1994; 244: 31-35
10. de Gaudemaris R, Chau NP, Mallion JM, for the Groupe de la Mesure, French Society of Hypertension. Home blood pressure: variability, comparison with office readings and proposal for reference values. J Hypertens 1994; 12: 831-838
11. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurements by physician and nurse. Hypertension 1987; 9: 209-215
12. Meyrs MG, Reeves. White coat phenomenon in patients receiving antihypertensive therapy. Am J Hypertens 1991; 4: 844-849
13. Burgess E. Office hypertension in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 684-685
14. Haynes RB, Mattson ME, Chobanian A et al. Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group. Hypertension 1982; 4: 415-423
15. Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403-1411
16. Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W. Does self-measurement of blood pressure improve patients compliance in hypertension? J Hypertens 1985 [Suppl. 1]; 3: 31-34
17. Mühlhauser I, Sawicki PT, Didjurgeit U, Jörgens V, Berger M. Uncontrolled hypertension in type 1 diabetes: assessment of patients' desires about treatment and improvement of blood pressure control by a structured treatment and teaching programme. Diabetic Med 1988; 5: 693-698
18. Sawicki PT, Mühlhauser I, Didjurgeit U, Berger M. Improvement of hypertension care by a structured treatment and teaching programme. J Hum Hypertens 1993; 7: 10-14
19. Sawicki PT, Didjurgeit U, Mühlhauser I, Heinemann L, Berger M. Near-normotension and near-normoglycaemia in blind type 1 diabetic patients with overt diabetic nephropathy. J Diab Campl 1990; 4: 179-183
20. Sawicki PT, Mühlhauser I, Didjurgeit U, Reimann M, Bender R, Berger M. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro- or macroproteinuria. Diabetic Med 1995; 12: 893-898
21. Sawicki PT, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933-938
22. Schurr E, Lahme W, Küppers H. Measurements of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980; 13: 26-29
23. Mühlhauser I, Bruckner I, Berger M et al. Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. Diabetologia 1987; 30: 681-690
24. Plum J, Schöning G, Grabensee B. Grenzen der GFR-Bestimmung mittels Inulin Clearance Messung bei Anwendung der Steady State Methode Ohne Urinsammlung. 27. Jahrestagung der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie, Zürich 1994
25. Sawicki PT, Heinemann LM, Berger M. Comparison of methods for determination of microalbuminuria in diabetic patients. Diabetic Med 1989; 6: 412-415
26. Sawicki PT, Berger M. Measuring progression of diabetic nephropathy. Review. Eur J Clin Invest 1994; 24: 651-655
27. SAS. SAS/STAT Guide for Personal Computers, Version 6 Edition. SAS Institute Inc., Cary, NC (1987)
28. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts longterm GFR decline in patients with non-diabetic renal disease. Kidney Int 1994 [Suppl.]; 45: S174-S178
29. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516
30. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-131
31. Bangstad HJ, Østerby R, Dahl-Jørgensen K, Berg KJ, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490
32. Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Br Med J 1995; 311: 973-977
33. Reichert P, Nilsson BY, Rosenquist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309
34. Królewski AS, Laffel LMB, Królewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-1255
35. Weidmann P, Boehlen M, de Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993; 8: 582-584
36. Mogensen CE, Keane WK, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084
37. Sawicki PT, Mühlhauser I, Baba T, Berger M. Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia 1990; 33: 121-124
38. Consensus Panel. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17: 1357-1361
39. Lewis EJ. Captopril and diabetic nephropathy. JAMA 1995; 273: 1831
40. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-342
41. Sawicki PT, Mühlhauser I, Berger M, Captopril, blood pressure, and diabetic nephropathy. JAMA 1994; 272: 1005
42. Sawicki PT, Berger M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 841-842
43. Bauer JH, Reams GP, Hewett J, Klacho D, Lau A, Messina C, Knaus V. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20: 443-457
44. Elving LD, Wetzels JMF, van Lier HJJ, de Nobel E, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994; 37: 604-609